FibroGen (FGEN) Misses Q2 EPS by 20c

FibroGen (NASDAQ: FGEN) reported Q2 EPS of ($0.90), $0.20 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $44.32 million versus the consensus estimate of $34.73 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Ready Capital prices $225M in new notes, redeems $350M due 2026
• B.Riley Assumes Anika Therapeutics (ANIK) at Buy